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Abstract: Scutellaria baicalensis (SB) is a traditional Chinese medicine for treating infectious and
inflammatory diseases. Our recent study shows potent antibacterial effects of nanoparticle-
encapsulated chlorhexidine (Nano-CHX). Herein, we explored the synergistic effects of the
nanoparticle-encapsulated SB (Nano-SB) and Nano-CHX on oral bacterial biofilms. Loading efficiency
of Nano-SB was determined by thermogravimetric analysis, and its releasing profile was assessed by
high-performance liquid chromatographyusing baicalin (a flavonoid compound of SB) as the marker.
The mucosal diffusion assay on Nano-SB was undertaken in a porcine model. The antibacterial effects
of the mixed nanoparticles (Nano-MIX) of Nano-SB and Nano-CHX at 9:1 (w/w) ratio were analyzed
in both planktonic and biofilm modes of representative oral bacteria. The Nano-MIX was effective
on the mono-species biofilms of Streptococcus (S.) mutans, S. sobrinus, Fusobacterium (F.) nucleatum,
and Aggregatibacter (A.) actinomycetemcomitans (MIC 50 µg/mL) at 24 h, and exhibited an enhanced
effect against the multi-species biofilms such as S. mutans, F. nucleatum, A. actinomycetemcomitans, and
Porphyromonas (P.) gingivalis (MIC 12.5 µg/mL) at 24 h that was supported by the findings of both
scanning electron microscopy (SEM) and confocal scanning laser microscopy (CLSM). This study
shows enhanced synergistic antibacterial effects of the Nano-MIX on common oral bacterial biofilms,
which could be potentially developed as a novel antimicrobial agent for clinical oral/periodontal care.
Keywords: nanotechnology; Scutellaria baicalensis; traditional Chinese medicine; chlorhexidine;
oral biofilms; antimicrobials
1. Introduction
Periodontal disease is a major global oral health burden and severe periodontitis accounts
primarily for multiple tooth loss in the adult population worldwide [1,2]. It badly affects oral health
and also significantly links with systemic diseases such as diabetes mellitus and cardiovascular
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disease [2,3]. Periodontal disease results from aberrant and exaggerated immuno-inflammatory
response to pathogenic plaque biofilms [4]. Therefore, various anti-biofilm and host modulatory
therapy have been tested for controlling periodontal disease [5]. Chlorhexidine (CHX) has long been
recognized as the golden standard of chemical plaque control for oral healthcare products. CHX
gluconate-containing mouthwash is a common chemical plaque control measure [6]. However, there
are certain side effects associated with CHX containing mouthwash, such as staining on the teeth,
unpleasant taste, allergic reactions, and occasionally numbness of the tongue [7,8]. In addition, CHX is
a classical disinfectant agent which kills all the bacteria without discriminating harmful pathogens.
It might also be toxic to the host cells [9]. This caveat has prompted researchers to look into alternative
anti-biofilm and host modulating agents and approaches.
Scutellaria baicalensis (SB) is a traditional Chinese medicine frequently used for treating infectious
and inflammatory diseases for thousands of years [10]. Chinese literature reports that it has
been used to manage periodontal disease [11]. Previous studies have confirmed that baicalin,
a flavonoid compound isolated from SB, possesses marked anti-inflammatory, antioxidative, and
immunomodulating effects [12–15]. It exhibits protective effect on the development of experimental
periodontitis [12] and benefits for controlling periodontal disease [13,16]. We have further shown that
baicalin could modulate P. gingivalis lipopolysaccharide-induced immuno-inflammatory response in
oral epithelia [14]. Interestingly, recent studies indicate that SB has potent antibacterial effects on oral
pathogens [17], and it could indeed inhibit bacterial quorum sensing activity [18]. A recent study
indicates that the combined use of another compound baicalein present in SB with antibiotics has
synergistic effects against oral bacteria [19].
Nano-encapsulation technique has currently become an exciting new approach to the delivery
of biologically active compounds and agents more effectively at specific biological niches [20,21].
Hence, nanotechnology has received great attention for developing new healthcare products and
drugs [22]. Recently, our team has successfully synthesized a novel mesoporous silica nanoparticle
(MSN)-encapsulated chlorhexidine (Nano-CHX), which demonstrates potent antibacterial effects on
oral biofilms [23]. It has also been shown that nanoparticle-encapsulated plant extracts enhance the
biological effectiveness via bioavailability and fast penetration with less cytotoxicity, reduced dosage of
the agents, and low costs [24]. Currently, nanotechnology has been increasingly applied in biomedical
research and development of novel drug delivery systems. Therefore, nano-encapsulated Chinese
herbal extracts or active compounds could enhance their biological effectiveness.
It has been well documented that oral mucosa serves as an attractive and preferred route for
systemic delivery of drugs, due to its featured biological structure, easy accessibility, high acceptance
by patients [25]. Compared to the skin, the buccal mucosa is far more permeable [26,27], which makes
it an instrumental and feasible approach to screening new drugs, assessing drug delivery efficacy,
bioavailability, and underlying mechanisms of drug transport as well as refining transbuccal drug
delivery. The Franz-Type Diffusion Cells model using porcine oral mucosa has been employed for
assay of drug diffusion and absorption [28]. With the similarity in membrane morphology, biological
structure and contents, and permeability barrier properties between human and porcine skins and
buccal mucosas, this ex vivo model has been well employed on investigation of the feasibility of drug
delivery and the underlying drug transport mechanism [29,30].
In the present study, we comprehensively investigated the anti-oral biofilm properties of the
Nano-MIX of novel MSN-encapsulated SB (Nano-SB) and Nano-CHX, with reference to our recent
findings of Nano-CHX alone against oral biofilms [23]. Meanwhile, the loading and releasing profiles
of Nano-SB were characterized, and the capacity of both Nano-SB and SB aqueous extract to penetrate
oral mucosa was examined using an ex vivo model of porcine buccal mucosa. Herein, we find the
significant synergistic antibacterial effects of the combined usage of Nano-SB and Nano-CHX at 9:1
(w/w) ratio against the mixed oral biofilms, such as S. mutans, F. nucleatum, A. actinomycetemcomitans,
and P. gingivalis.
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2. Results
2.1. Loading and Releasing Profiles of Nano-SB
The aqueous extract of SB was swelled and loaded into MSN. The percentage of SB extract loaded
to the nanoparticles was determined by thermogravimetric analyses. As shown in Figure 1, the weight
loss of Nano-SB was 5.2% from 100 to 900 ˝C. As the weight loss of blank nanoparticles was found to
be 3.2% during this range of temperature, the SB loading efficiency was calculated to be 2.0% after a
background subtraction with the blank nanoparticles.
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Figure 1. The thermogravimetric analysis on the weight losses of nanoparticle-encapsulated
Scutellaria baicalensis (Nano-SB) (5.2%) (upper) and blank nanoparticles (3.2%) (lower) between 100 ˝C
and 900 ˝C.
The high-performance liquid chromatography (HPLC) analysis of Nano-SB was then performed
with reference to baicalin per se and SB aqueous extract. The retention time of baicalin, the biomarker
of SB, was assigned at 12.5 min. It was noted that the SB content trapped in MSN could be released in
water at 24 h, indicating that Nano-SB was able to release baicalin (Figure 2).
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Figure 2. The high-performance liquid chromatography (HPLC) profiles of (A) baicalin; (B) SB aqueous
extract; and (C) Nano-SB. Detection was performed at 274 nm, and the retention time of baicalin was
assigned at 12.5 min.
2.2. The Penetration Capacity of Nano-SB through Porcine Buccal Mucosa
As shown in Table 1, the diffusion experiment found that 14.6% of baicalin, the bioactive
component from the Nano-SB aqueous extract, was retained within the mucosal membrane after
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2 h of treatment, with reference to 9.8% of SB extract. However, after 6 h of treatment, 46.7% of baicalin
penetrated through the oral mucosal membrane, with reference to 72.5% of SB extract. Taken together,
the total retention rate (5.8%) and penetration rate (46.7%) of Nano-SB reached 52.5%. Notably, such
diffusive and penetrative effects of Nano-SB acted in a relatively slow mode with reference to SB
(14.6% vs. 48.8% at 2 h; and 52.5% vs. 76.0% at 6 h).
Table 1. Penetration percentage of SB aqueous extract and Nano-SB during the diffusion cell experiment
after treatments of 2 h or 6 h.
Duration of
Treatment Sample
Original Amount
of Baicalin (µg)
Baicalin Retained
within Mucosa (%)
Baicalin Penetrated to
Receiver Chamber (%)
2 h
SB 927 9.8% 39.0%
Nano-SB 20 14.6% 0.0%
6 h
SB 927 3.5% 72.5%
Nano-SB 20 5.8% 46.7%
2.3. Antibacterial Effects of Nano-MIX on Planktonic Bacteria and Mono- and Multi-Species Oral Biofilms
To investigate the synergistic effects of the mixed nanoparticles (Nano-MIX), Nano-SB and
Nano-CHX at various ratios were tested in pilot experiments. The 9:1 (w/w) ratio of Nano-SB and
Nano-CHX was determined appropriately, and the Nano-MIX was then prepared for the subsequent
experiments. The weight percentages of SB and CHX in the Nano-MIX were 1.80% and 2.02%,
respectively. The minimum inhibitory concentration (MIC, µg/mL) values of Nano-MIX on the
planktonic mode and mono-species biofilms of selected oral pathogens with reference to the blank
nanoparticles are presented in Table 2. Notably, the Nano-MIX treatment for 24 h effectively inhibited
the mono-species biofilms of S. mutans, S. sobrinus, F. nucleatum, and A. actinomycetemcomitans at a low
MIC of 50 µg/mL. The Nano-MIX also inhibited the mono-species biofilms of Enterococccus (E.) faecalis
with a relatively high MIC of 200 µg/mL.
Table 2. The minimal inhibitory concentration (MIC, µg/mL) of the mixed nanoparticles (Nano-MIX)
of Nano-SB and nanoparticle-encapsulated chlorhexidine (Nano-CHX) at 9:1 (w/w) ratio against the
planktonic mode and mono-species biofilms of selected oral bacteria at 24 h.
Stain Planktonic Mode Mono-Species Oral Biofilms
S. mutans 50 50
S. sobrinus 50 50
F. nucleatum 25 50
A. actinomycetemcomitans 50 50
E. faecalis 50 200 *
* Significant difference from the planktonic mode, p < 0.05.
Moreover, we further examined the preventive action of Nano-MIX on the formation of three
selected multi-species biofilms at 24 h and 48 h. Interestingly, the Nano-MIX had potent antibacterial
effects on the mixed-species biofilms of S. mutans, F. nucleatum, and P. gingivalis; S. sobrinus, F. nucleatum,
and P. gingivalis; and S. mutans, F. nucleatum, A. actinomycetemcomitans, and P. gingivalis, at low MIC
levels of 12.5 µg/mL (24 h) and 50 µg/mL (48 h), respectively (Table 3). The anti-biofilm effect on
multi-species biofilms of S. mutans, F. nucleatum, A. actinomycetemcomitans, and P. gingivalis at 24 h
was further confirmed by both confocal scanning laser microscopy (CLSM) and scanning electron
microscopy (SEM). The findings of CLSM (Figure 3A,B) and SEM images (Figure 3C,D) showed that
the Nano-MIX treatment markedly affected the multi-species biofilms with few remaining isolated
bacterial cells, with reference to the controls treated with blank nanoparticles.
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Table 3. The minimal inhibitory concentration (MIC, µg/mL) of the mixed nanoparticles (Nano-MIX)
of Nano-SB and nanoparticle-encapsulated chlorhexidine (Nano-CHX) at 9:1 (w/w) ratio against the
selected multi-species biofilms of oral bacteria at 24 h and 48 h.
Multi-Species Biofilms 24 h 48 h
S. mutans, F. nucleatum and P. gingivalis 12.5 50 *
S. sobrinus, F. nucleatum and P. gingivalis 12.5 50 *
S. mutans, F. nucleatum, A. actinomycetemcomitans and P. gingivalis 12.5 50 *
* Significant difference from 24 h, p < 0.05.
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Figure 3. Effect of the Nano-MIX on the multi-species biofilms of S. mutans, F. nucleatum,
A. actinomycetemcomitans, and P. gingivalis at 24 h. The confocal scanning laser microscopy (CLSM) (A,B)
and scanning electron microscopy (SEM) images (C,D) showing comparative antibacterial effects of the
Nano-MIX treatment (B,D) on the mixed-species oral biofilms with reference to the blank nanoparticles
(A,C), respectively.
3. Discussion
The characters of the MSN used in the present study have been previously described, presenting
an average diameter of 140 nm with both pore size and volume of about 2.5 nm and 1.0 cm3/g,
respectively; the CHX loading efficiency of Nano-CHX is 20.2% [23]. In the present study, the SB
loading efficiency of Nano-SB is 2.0%. The loading efficiency of a substrate towards the mesopores
with a fixed diameter ~2 nm of the silica nanoparticle is governed by the molecular size and shape,
polarity of the substrate, and the solvent and method used in the loading process. Moreover, the HPLC
analysis reveals that the Nano-SB enables the containment and release of baicalin, the marker of SB.
Hence, the nano-encapsulation and releasing process of SB have been effectively undertaken.
CHX as an essential ingredient in commonly used mouthwash is highly effective for controlling
plaque biofilms [6]. However, it has been reported that CHX has some adverse effects like tooth
staining and hypersensitive response [7,8]. SB or its active species have been loaded to the magnetic
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nanoparticles [31–33] and chitosan nanoparticles [34], and these studies show that the nanoparticles
loaded with SB derivatives exhibit an enhanced drug delivery percentage, increased apoptosis of
cancer cells, and a reversal of multidrug resistance. The present study investigated for the first time
the synergistic effects of Nano-SB and Nano-CHX on selected oral biofilms. Furthermore, our initial
proof-of-concept experiment on the penetration of Nano-SB through porcine oral mucosa assessed
the active interactions of Nano-SB with oral mucosa tissue and its compatibility for the practical
oral applications. Furthermore, a significantly reduced amount of Nano-CHX in the Nano-MIX with
Nano-SB and Nano-CHX at 9:1 (w/w) ratio would minimize the unwanted effects of CHX for potential
clinical benefits. The findings showed that the Nano-MIX treatment for 24 h was relatively more
effective against the planktonic mode of S. sobrinus (MIC, µg/mL: 50 vs. 100), F. nucleatum (25 vs. 50),
and E. faecalis (50 vs. 100), with reference to Nano-CHX alone, shown in our recent study [23]. Notably,
this trend was also observed against mono-species biofilms, as Nano-MIX had a comparatively lower
MIC than the Nano-CHX for S. mutans (50 vs. 100), F. nucleatum (50 vs. 100), A. actinomycetemcomitans
(50 vs. 100), and especially S. sobrinus (50 vs. 200). As such, the Nano-MIX exhibited one-fold lower MIC
against S. mutans, F. nucleatum, and A. actinomycetemcomitans, and 4-fold lower MIC against S. sobrinus.
Furthermore, Nano-MIX also demonstrated more effective preventive actions against the
formation of multi-species biofilms of S. sobrinus, F. nucleatum and P. gingivalis, and S. mutans,
F. nucleatum, A. actinomycetemcomitans and P. gingivalis after 24 h treatment, showing one-fold lower
MIC with reference to the Nano-CHX alone (12.5 vs. 25 µg/mL), respectively [23]. The anti-biofilm
effect on S. mutans, F. nucleatum, A. actinomycetemcomitans and P. gingivalis was well supported by
the findings of SEM and CLSM images. Similarly, some recent studies have indicated the enhanced
antimicrobial activity when pure drugs are incorporated into nanoparticle carriers [35,36]. Hence,
nanotherapy may bring clinical benefits to the patients suffering from oral biofilm-induced infections
and inflammation (e.g. periodontal disease) in the future, although more studies are warranted to
translate the current findings into clinical usage.
The present study indicates the enhanced synergistic antimicrobial effects of the Nano-MIX
on common oral bacterial biofilms. Further investigation is highly warranted to refine the
protocol for optimal antimicrobial effectiveness. It is potentially possible to develop novel
nanoparticle-encapsulated multiple agents such as herbal medicine and pure CHX for better oral and
periodontal care.
4. Materials and Methods
4.1. SB Extract and Nano-CHX
SB aqueous extract was kindly provided by the Hong Kong Premier Concentrated Chinese Herbs
Ltd., Kowloon, China, with an extraction yield of 33.3%. Pure chlorhexidine (base form) and other
chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA). MSN and Nano-CHX were
prepared as described in our recent study [23].
4.2. Thermogravimetric Analysis of SB Loading in MSN
SB extract (50 mg) was dissolved in ethanol (5 mL). The undissolved extracts or compounds
were filtered off using a membrane with a pore size of 0.2 micron. The concentration of filtrate was
fixed at 7 mg/mL. 50 mg of MSN were then added into 4 mL of the filtrate. After incubation at room
temperature for 24 h, the mixture was centrifuged. The SB aqueous extract-loaded MSNs (Nano-SB)
were collected by membrane filtration. Its loading effeminacy was determined with reference to
blank MSNs through thermogravimetric analyses by the Perkin Elmer TGA-6 (Waltham, MA, USA),
according to an established protocol [20].
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4.3. High-Performance Liquid Chromatography (HPLC) Analyses
The chromatographic profiles of baicalin (a biomark of SB), the SB aqueous extract, and the
released Nano-SB were analyzed by a HPLC System, Hewlett Packard Agilent 1100 series equipped
with G1329A ALS Autosampler and G1315A Diode Array Detector (Agilent Technologies, Waldbronn,
Germany). The solvents were then pre-filtered with the Millipore filter disk (0.45 µm) (Millipore,
Darmstadt, Germany) and de-gassed. A gradient elution was undertaken using the mobile phases A
(methanol) and B (water/phosphoric acid 99.8/0.2 v/v). The elution was carried out with a gradient
procedure as follows: 0–8 min, 45% B; 8–20 min, from 45% B to 48% B. The flow rate was set at
1.0 mL/min, and the detection was made at 278 nm for baicalin. Ten microliters of each sample were
injected into the Ultrasphere ODS C-18 column (Beckman Instrument Inc., Fullerton, CA, USA) after
filtration via a filter disk (0.45 µm). The baicalin in the SB aqueous extract and released Nano-SB was
then identified by comparing the retention times. The system was monitored by a PC with the 32 Karat
Software (Beckman Instrument Inc., Fullerton, CA, USA) for data collection, integration, and analysis.
4.4. Preparation of Porcine Buccal Mucosal Membranes and Diffusion Assays
Porcine buccal mucosal membranes were used for the in vitro trans-buccal mucosal experiments,
to determine the penetration profile of SB and Nano-SB. Fresh porcine heads were obtained from
commercial butcher supplier. They were then immediately dissected, and the buccal mucosal
membrane was freshly isolated from porcine oral cavity following standard protocol as previously
described [25]. In brief, full thickness of the mucosal membrane was cut and liberated from the
underlying cartilage using a scalpel. Any adhering subcutaneous fats and tissues were carefully
removed. The membrane was then cut into 1.77 cm2 sections and stored at ´80 ˝C until further usage.
The diffusion experiments were performed using a diffusion cell system (Taiping Business
Mansion, Nanjing, China), consisting of six diffusion cells, diffusion cell drive, and circulating water
bath for control of diffusion cells temperature as previously described [37]. Each diffusion cell included
a donor and receiving chamber, with a magnetic stirrer at the bottom to ensure thorough mixing of the
sample solution at the receiving chamber. The diffusion cell exhibited a diffusion-available surface
area of 1.77 cm2. Phosphate buffered saline (PBS) (Invitrogen, San Diego, CA, USA) was used as the
diffusion medium, with constant stirring at 600 rpm. Temperature was maintained at 37 ˘ 0.5 ˝C to
ensure all membranes was kept at approximately 32 ˝C throughout the experiment. Prior to use, all
porcine buccal mucosal membranes were soaked in pre-warmed PBS for 5 min to allow hydration
of the membranes. All membranes were then carefully placed on top of each of the diffusion cells,
avoiding the presence of air bubbles between the membranes and buffer solution. Donor chambers
were placed on top of the membranes, and the samples were applied on top of the membranes. All
diffusion cells were clipped tightly to avoid evaporation. To determine the amount of baicalin retained
in the membrane, it was extracted by soaking into 2 mL of methanol followed by sonication for 1 h;
for determining the amount of baicalin diffused through the membrane, the receiver medium was
withdrawn at determined intervals. All samples were then analyzed by HPLC.
4.5. Anti-Biofilm Properties of the Nano-MIX (Nano-SB and Nano-CHX at 9:1 w/w)
Representative oral bacteria including S. mutans (ATCC 35668), S. sobrinus (ATCC 33478),
F. nucleatum (ATCC 25586), A. actinomycetemcomitans (ATCC 43718), E. faecalis (ATCC 29212), and
P. gingivalis (ATCC 33277), derived from the archival collection at the Centralized Research Laboratory
of the Faculty of Dentistry, The University of Hong Kong, were used in the present study. The MIC of
planktonic bacteria was assessed, and mono- and mixed-species biofilms were prepared according to
our established procedures [23]. The mixed-species biofilms were made under identical experimental
conditions and then tested on the anti-biofilm effects of the nanoparticles at 24 h and 48 h, including
(i) S. mutans, F. nucleatum and P. gingivalis; (ii) S. sobrinus, F. nucleatum and P. gingivalis; and (iii) S. mutans,
F. nucleatum, A. actinomycetemcomitans and P. gingivalis. In separate experiments, biofilms were formed
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in 1 ˆ 1 cm sterilized polystyrene coupons (IWAKI, Tokyo, Japan). The blank silica nanoparticles
were employed as the controls. The multi-species biofilm samples of S. mutans, F. nucleatum,
A. actinomycetemcomitans and P. gingivalis were subjected to further assessments by both SEM (Hitachi,
Tokyo, Japan) and CLSM (Olympus, Tokyo, Japan) at 24 h as previously described [23], in order to
confirm the in vitro findngs.
4.6. Statistical Analysis
Student’s t-test or analysis of variance (ANOVA) as appropriate was employed by using the
statistical package for the social sciences (SPSS) Statistics (Version 21.0, IBM Corp. Armonk, NY, USA)
to determine the statistical significance of MIC between the groups of planktonic and biofilm modes of
the bacteria tested, as well as the different time points in the experiments.
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Abbreviations
The following abbreviations are used in this manuscript:
SB Scutellaria baicalensis
Nano-CHX Nanoparticle-encapsulated chlorhexidine
Nano-SB Nanoparticle-encapsulated SB
HPLC High-performance liquid chromatography
Nano-MIX Nano-SB and Nano-CHX
SEM Scanning electron microscopy
CSLM Confocal scanning laser microscopy
MSN Mesoporous silica nanoparticle
PBS Phosphate buffered saline
MIC Minimum inhibitory concentration
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